Methods and kits for reducing the likelihood of implantation failure and pregnancy-related disorders in recipients of artificial insemination

Abstract

Methods and kits for preventing or reducing the likelihood of implantation failure and pregnancy-related disorders in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).

1 - 38 . (canceled) 
     
     
         39 . A kit for reducing the likelihood of implantation failure and pregnancy-related disorders in a recipient of artificial insemination, comprising multiple doses of granulocyte colony-stimulating factor (G-CSF) in unit dosage forms; and a label with instructions for using the G-CSF to reduce the likelihood of implantation failure and pregnancy-related disorders. 
     
     
         40 . The kit of  claim 39 , wherein said pregnancy-related disorders include miscarriage, spontaneous abortion, preterm labor and preeclampsia. 
     
     
         41 . The kit of  claim 39 , wherein said G-CSF is formulated for subcutaneous administration. 
     
     
         42 . The kit of  claim 39 , wherein said G-CSF is formulated for intramuscular administration. 
     
     
         43 . The kit of  claim 39 , wherein said G-CSF is formulated for intravascular administration. 
     
     
         44 . The kit of  claim 39 , wherein each unit dosage of G-CSF further comprises at least one other active compound. 
     
     
         45 . The kit of  claim 44 , wherein said other active compound is another colony-stimulating factor (CSF), erythropoietin or stem cell factor. 
     
     
         46 . The kit of  claim 45 , wherein said CSF is granulocyte-macrophage colony stimulating factor (GM-CSF) or macrophage colony stimulating factor (M-CSF). 
     
     
         47 . The kit of  claim 44 , wherein said at least one other active compound comprises an anti-inflammatory agent. 
     
     
         48 . The kit of  claim 44 , wherein said at least one other active compound comprises an interleukin. 
     
     
         49 . The kit of  claim 39 , wherein said G-CSF is contained in an implantable device for slow release after implantation of the device. 
     
     
         50 . The kit of  claim 39 , wherein said G-CSF is contained in a transdermal patch for slow release after application of the transdermal device. 
     
     
         51 . The kit of  claim 39 , wherein said G-CSF is contained in a vaginal ring. 
     
     
         52 . The kit of  claim 39 , wherein said G-CSF is embedded in an inert matrix. 
     
     
         53 . The kit of  claim 39 , wherein said G-CSF is in lyophilized form. 
     
     
         54 . The kit of  claim 39 , wherein the granulocyte colony-stimulating factor (G-CSF) is formulated in unit dosage form for implantation failure; and wherein the label contains instructions for using the G-CSF to reduce the likelihood of implantation failure. 
     
     
         55 . The kit of  claim 39 , wherein the granulocyte colony-stimulating factor (G-CSF) is formulated in unit dosage form for spontaneous abortion; and wherein the label contains instructions for using the G-CSF to reduce the likelihood of spontaneous abortion. 
     
     
         56 . The kit of  claim 39 , wherein the granulocyte colony-stimulating factor (G-GSF) is formulated in unit dosage form for preterm labor; and wherein the label contains instructions for using the G-CSF to reduce the likelihood of preterm labor. 
     
     
         57 . The kit of  claim 39 , wherein the granulocyte colony-stimulating factor (G-CSF) is formulated in unit dosage form for preeclampsia; and wherein the label contains instructions for using the G-CSF to reduce the likelihood of preeclampsia.